Showing results (1081-1090 of 1,094) with videos related to
Sort By:
Pageof 110
Journal of the National Cancer Institute|July 3, 2018
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable TargetsDamir Varešlija, Nolan Priedigkeit, Ailís Fagan, et al.Journal of Neurosurgery|November 9, 2019
Early postmarket results with PulseRider for treatment of wide-necked intracranial aneurysms: a multicenter experienceVisish M Srinivasan, Aditya Srivatsan, Alejandro M Spiotta, et al.ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)Jun Li, Lawrence J Kennedy, Steven J Walker, et al.Neurogenetics|August 29, 2001
Genetic susceptibility to MS: a second stage analysis in Canadian MS familiesD A Dyment, C J Willer, B Scott, et al.Nature Communications|October 7, 2018
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapyDominiek Smeets, Ian S Miller, Darran P O'Connor, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2018
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With BevacizumabErik van Dijk, Hedde D Biesma, Martijn Cordes, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 27, 2013
Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteriaJoe Bentz, Michael P O'Connor, Dallas Bednarczyk, et al.The Review of Scientific Instruments|July 3, 2016
The cryogenic storage ring CSRR von Hahn, A Becker, F Berg, et al.Journal of Medicinal Chemistry|May 25, 2017
Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 InhibitorXiang-Yang Ye, Stephanie Y Chen, Shung Wu, et al.Nature Genetics|July 22, 2020
Prostate cancer reactivates developmental epigenomic programs during metastatic progressionMark M Pomerantz, Xintao Qiu, Yanyun Zhu, et al.Pageof 110